anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: claimed invention relates to field of medicine. Claimed is method of chemical-therapeutic treatment of locally spread unresectable glandular cancer of pelvis minor organs. Introduction of medication, containing 5-fluorouracil, metronidazole water for injections, low molecular polyethylene, emulsifier T-2, olive oil, lutrol F127 and cremofor RH40 is performed in dose 1 ml into cellular spaces, surrounding organ, ligaments and under serous membrane of organs in area of cancer tumour. Single introduction must not exceed 5.0 g of chemical preparation. ^ EFFECT: application of invention insures creation of prolonged to 4 weeks local depot of antitumor medication, what results in reduction of intoxication and reduction of medication dose. ^ 2 ex
Drug delivery articles, resident articles, and retrieval systems e.g., for gram-level dosing, are generally provided. In some embodiments, the articles are configured for transesophageal administration, transesophageal retrieval, and/or gastric retention to/in a subject. In certain embodiments, the article includes dimensions configured for transesophageal administration with a gastric resident system. In some cases, the article may be configured to control drug release e.g., with zero-order drug kinetics with no potential for burst release for weeks to months. In some embodiments, the articles described herein comprise biocompatible materials and/or are safe for gastric retention. In certain embodiments, the article includes dimensions configured for transesophageal retrieval. In some cases, the articles described herein may comprise relatively large doses of drug (e.g., greater than or equal to 1 gram).
Hepatocellular carcinoma (HCC) is a common cancer and is diagnosed at an earlier stage and with increasing frequency because of the wider implementation of screening programs. Whether liver resection or local ablation should be the first-line treatment in early HCC remains a hot topic for debate. Both are regarded as acceptable curative treatment for early HCC in many international guidelines. Underlying liver function is the key in treatment selection. The general consensus is that liver resection should be the treatment of choice in patients with good liver function while local ablation should be considered in patients with poor liver function. There exists a group of patients with apparently good liver function that harbor significant liver cirrhosis which is not easily picked up by the current assessment or scoring systems. Liver resection in this group of patients is burdened by potentially life-threatening complications and the overall survival is limited by their underlying liver cirrhosis. This is particularly important in early HCC as local ablation is another curative treatment option. In order to improve the prognosis of patients with early HCC, it is important to identify (1) patients with liver dysfunction to the extend that the risk of liver resection will outweigh the survival benefit it provides; (2) the best ablative method for HCC.

The investigators propose to carry out a prospective randomized controlled study to compare the treatment outcome of microwave ablation with liver resection in patients with borderline liver function whose HCC that are amendable to both liver resection and microwave ablation.
Participants will receive similar treatment as Acu-TENS groups via identical-looking TENS devices with the electrical circuit disconnected.Participants will also receive a set of instructions relating to SHP. SHP is a set of instructions designed to help with sleep and promote healthy sleeping habits. Participants will be instructed to read the guide after the baseline assessment (T0).
Either recombinant human growth hormone (daily subcutaneous injections of 0.05 mg/kg/day of GH at discharge \[somatropin, Genotropin, Pfizer, New York, NY\]; 0.025 mg/kg/day of GH titrated the week before discharge) or placebo (n=31) will be administered to adult burned subjects (n= 31, 18-85 years) after screening and voluntary consent who have ≥30% TBSA assessed by either the Lund and Browder chart or the 'rule of nines' method during excisional surgery. It will be administered daily for 9 months beginning the week before discharge, and the primary and secondary endpoints will be collected during the acute hospital stay, discharge, and long-term follow-up visits (6, 12, 18, and 24 months after burn injury). Additionally, subjects will be contacted frequently \[most likely 1 week, 1 month, and 2 months post discharge by telephone\] to ensure that there are no adverse events or concerns with their study drug, as well as visit with them during their clinical visits that address their post-burn needs. All subjects will receive similar standard medical care and treatment from the time of emergency admission until their discharge.

Growth hormone will be used to potentially attenuate losses in height, weight, muscle and bone, reverse the oxidative stress of burn injury and, in the process, decrease the secondary consequences of burn injury, including organ dysfunction. This may improve the quality of life of the burn patient by preventing pathophysiology that may result from muscle and bone loss and may reduce hospital stay. Our research will lay the foundation for the future development of effective, safe, and economic therapeutic interventions to treat burn injury-associated metabolic abnormalities. Also, it will provide the basis for the development of supplemental regulations and pharmacotherapy to treat burn patients with GH. The risks are very reasonable in relation to the anticipated benefits to our subjects because a) GH at a higher dose has been tested in pediatric burned subjects with minor adverse events, and b) the subjects will be monitored consistently.
Cardiac tissue remodeling is characterized by altered heart tissue architecture and dysfunction, leading to heart failure. Sustained activation of the renin-angiotensin-aldosterone system (RAAS) greatly promotes the development of myocardial remodeling. Angiotensin II (Ang II), which is the major component of RAAS, can directly lead to cardiac remodeling by inducing an inflammatory response. Schisandrin B (Sch B), the active component extracted from the fruit of Schisandra chinensis (Turcz.) Baill has been shown to exhibit anti-inflammatory activity through its ability to target TLR4 and its adaptor protein, MyD88. In this study, we explored whether Sch B alleviates Ang II-induced myocardial inflammation and remodeling via targeting MyD88. Sch B significantly suppressed Ang II-induced inflammation as well as increased the expression of several genes of tissue remodeling (β-Mhc, Tgfb, Anp, α-Ska) both in vivo and in vitro. These protective effects of Sch B were due to the inhibition of recruitment of MyD88 to TLR2 and TLR4, suppressing the Ang II-induced NF-κB activation and reducing the following inflammatory responses. Moreover, the knockdown of Myd88 in cardiomyocytes abrogated the Ang II-induced increases in the production of inflammatory cytokines and expression of remodeling genes. These findings provide new evidence that the mechanism of Sch B protection was attributed to selective inhibition of MyD88 signaling. This finding could pave the way for novel therapeutic strategies for myocardial inflammatory diseases.
An amantadine hydrochloride soft capsule and a preparation method therefor. The amantadine hydrochloride soft capsule comprises: a content mixed liquor and a soft capsule shell. The content mixed liquor is a suspension comprising amantadine hydrochloride, soybean oil, lecithin, a cera alba mixture and methyl silicone oil, the cera alba mixture comprising cera alba, hydrogenated vegetable oil type I and hydrogenated vegetable oil type II. In the amantadine hydrochloride soft capsule produced from the formulation above, cera alba is used as a suspending agent to increase the viscosity of the formulation and maintain the uniformity of the drug in the formulation, and lecithin is used as an emulsifier to uniformly disperse amantadine hydrochloride in the content mixed liquor and increase stability. According to the bioequivalence test for consistency evaluation, the developed soft capsule formulation has a consistency of more than 95% with the brand name formulation and achieves the same clinical effect as the brand name formulation. In addition, the preparation method has a simple production process and does not have the problem of capsule leakage or deformation.
This is a CALGB Leukemia Tissue Bank project that makes use of tissue from patients who have previously provided their consent. Diagnostic and follow-up samples from acute myeloid leukemia (AML) patients treated on CALGB protocols 9621, 9720 and 19808, and who have been registered on the mandatory companion Leukemia Tissue Bank Protocol CALGB 9665 will be used.
512,090. Medicinal plant triturations. MADAUS, G. G. W., MADAUS, F. J. N., and MADAUS, J. M. T. Sept. 15, 1938, No. 26990. [Class 81 (i)] Therapeutic triturations from fresh plants rich in alkaloids are produced by triturating them with triturating media and gradually drying the product with cold air, there being added prior to the drying step and preferably during the trituration stage a substance having an acid reaction. The triturating media are defined as substances having no therapeutic value but when ground with the plants assist in their fine comminution. Examples are grape, milk, cane, fruit, invert and like sugars, polysaccharides such as starch, dextrin and amyloses and other adsorptive media such as colloidal silica, loam, kaolin, fullers earth and aluminium hydroxide. Suitable acids are malic, lactic, citric, tartaric acetic, hydrochloric or sulphuric acids and similar acids. Their function is to stabilize the alkaloids, e.g., to prevent the racemisation of hyoscyamine to atropine, or to fix the volatile alkaloids such as conine, nicotine or ephedrin. Acid buffer mixtures such as those containing monosodium phosphate or calcium lactate may be added, while substances which swell in the presence of water such as polymeric carbohydrates, pectin, starch, tragacanth may be added during trituration. The trituration may be carried out in roller mills to give a product passing through a screen having 6,000 meshes per sq. cm. The drying is carried out at a temperature not exceeding 30‹C. and preferably at 20‹C. to a moisture content of 2 per cent. The product may be subjected to further subdivision and may be mixed with other therapeutically active substances.
Atrial fibrillation (AF), the most common sustained cardiac arrhythmia, is not a dichotomous disease trait. Technological innovations enable long-term rhythm monitoring in many patients and can estimate AF burden. These technologies are already used to detect and monitor AF. This review describes the relation between AF burden and outcomes and potential effects of AF burden reduction. A lower AF burden is associated with a lower risk of stroke and heart failure in patients with AF: stroke risk without anticoagulation is lower in patients with device-detected AF and a low AF burden (stroke rate 1%/year) than in patients with persistent and permanent AF (stroke rate 3%/year). Paroxysmal AF shows intermediate stroke rates (2%/year). Atrial fibrillation burden-reducing interventions can reduce cardiovascular outcomes in patients with AF: early rhythm control reduces cardiovascular events including stroke and heart failure in patients with recently diagnosed AF and cardiovascular conditions. In patients with heart failure and AF, early rhythm control and AF ablation, interventions that reduce AF burden, reduce mortality and heart failure events. Recent technological innovations allow to estimate AF burden in clinical care, creating opportunities and challenges. While evidence remains limited, the existing data already suggest that AF burden reduction could be a therapeutic goal. In addition to anticoagulation and treatment of cardiovascular conditions, AF burden reduction emerges as a therapeutic goal. Future research will define the AF burden that constitutes a relevant risk of stroke and heart failure. Technologies quantifying AF burden need careful validation to advance the field.
PURPOSE: We aimed to investigate early effects of exogenously administered adropin (AD) on neurological function, endothelial nitric oxide synthase (eNOS) expression, nitrite/nitrate levels, oxidative stress, and apoptosis in subarachnoid hemorrhage (SAH).
METHODS: Following intracerebroventricular AD administration (10 µg/5 µl at a rate of 1 µl/min) SAH model was carried out in Sprague-Dawley rats by injection of autologous blood into the prechiasmatic cistern. The effects of AD were assessed 24 h following SAH. The modified Garcia score was employed to evaluate functional insufficiencies. Adropin and caspase-3 proteins were measured by ELISA, while nitrite/nitrate levels, total antioxidant capacity (TAC) and reactive oxygen/nitrogen species (ROS/RNS) were assayed by standard kits. eNOS expression and apoptotic neurons were detected by immunohistochemical analysis.
RESULTS: The SAH group performed notably lower on the modified Garcia score compared to sham and SAH + AD groups. Adropin administration increased brain eNOS expression, nitrite/nitrate and AD levels compared to SHAM and SAH groups. SAH produced enhanced ROS/RNS generation and reduced antioxidant capacity in the brain. Adropin boosted brain TAC and diminished ROS/RNS production in SAH rats and no considerable change amongst SHAM and SAH + AD groups were detected. Apoptotic cells were notably increased in intensity and number after SAH and were reduced by AD administration.
CONCLUSIONS: Adropin increases eNOS expression and reduces neurobehavioral deficits, oxidative stress, and apoptotic cell death in SAH model. Presented results indicate that AD provides protection in early brain injury associated with SAH.
Studies of prilocaine in animals to evaluate the carcinogenic and mutagenic potential or the effect on fertility have not been conducted.

Chronic oral toxicity studies of ortho-toluidine, a metabolite of prilocaine, in mice (150–4800 mg/kg) and rats (150–800 mg/kg) have shown that ortho-toluidine is a carcinogen in both species. The lowest dose corresponds to approximately 50 times the maximum amount of ortho-toluidine to which a 50 kg subject would be expected to be exposed following a single injection (8 mg/kg) of prilocaine.

Ortho-toluidine (0.5 mg/mL) showed positive results in Escherichia coli DNA repair and phage-induction assays. Urine concentrates from rats treated with ortho-toluidine (300 mg/kg, orally) were mutagenic for Salmonella typhimurium with metabolic activation. Several other tests, including reverse mutations in five different Salmonella typhimurium strains with or without metabolic activation and single strand breaks in DNA of V79 Chinese hamster cells, were negative.
Synbiotics have been used as biotherapeutic supplements for prevention of new-born calf gastrointestinal disorders. Present study was conducted to evaluate the impact of fructo-oligosaccharide, mannan-oligosaccharide and inulin along with Lactobacillus plantarum CRD-7 and Lactobacillus acidophilus NCDC15 on the nutrient digestibility, growth performance and faecal microbial population of pre-ruminant buffalo calves. Twenty-four Murrah calves (5 days old) were randomly assigned to four groups of six calves in each using randomized block design. Calves in Group I (control) received only a basic diet of milk, calf starter and berseem with no additives. Calves in Group II (SYN1) were fed 6 g fructo-oligosaccharide (FOS) + Lactobacillus plantarum CRD-7 (100 ml). Calves in Group III (SYN2) were fed 9 g inulin + L. plantarum CRD-7 (50 ml), while calves in Group IV (SYN3) received 4 g MOS + L. acidophilus NCDC15 (200 ml) as fermented milk having 108 CFU/ml/calf/day in addition to the basal diet. The results revealed that digestibility of dry matter, crude protein, ether extract and average daily gain were all higher (P < 0.05) in SYN1 as compared to control group. The antioxidant enzyme activity, humoral and cell mediated immunity performed well in SYN1, SYN2 and SYN3 as compared to control. Diarrhoea and faecal scouring were lower (P < 0.05) in all supplemented groups than control. Faecal Lactobacilli and Bifidobacterium counts were also higher in SYN1 group followed by SYN2 and SYN3. Faecal ammonia, lactate, pH, and volatile fatty acids level were increased in SYN1 supplemented groups. The synbiotic combination of 6 g FOS + L. plantarum CRD-7 had better response on digestibility, average daily gain, antioxidant enzymes, immune response, faecal microbiota and metabolites and also reduce the faecal score and diarrhoea incidence. Therefore, supplementation of 6 g FOS + L. plantarum CRD-7 can be advised for general use in order to promote long-term animal production.
The study will involve patients diagnosed with HER2-positive unresectable or mBC since the earlier date between the date of trastuzumab emtansine (\[T-DM1\] Kadcyla) becoming available through reimbursement or patient access programme as a valid local treatment option or 01 January 2017 and who received at least 1 LOT. The data will be collected from the date of diagnosis of unresectable or mBC (index date) to the end of follow-up (ie, until death, the last medical record entry, or date of data extraction, whichever is earlier). The study will not have any study-specific patient visits or a longitudinal follow-up. All available data will be extracted from patients' medical records or obtained from patients themselves after obtaining an informed consent unless a waiver is granted by the local Institutional Review Board (IRB)/Institutional Ethics Committee (IEC)/Ethics Committee (EC). The informed consent may be obtained at the time of patients routine clinical care visit to the oncology centre. The data on different types of treatment received by the patients, socio-demographics, and clinico-pathological characteristics will be extracted from patients medical records up to the date informed consent was obtained.

This study will be conducted in non-US and non-European countries including Australia, Brazil, Hong Kong, Korea, Singapore and Taiwan. The total number of patients in the study will be approximately a minimum of 570 and a maximum of 830 patients. The study will be implemented at approximately 50 to 100 oncology centres spanning across 6 countries in the AstraZeneca (AZ) International Region (ie, non-US, non-European countries).
PURPOSE: To obtain an ultraviolet radiation absorbing composition containing an ultraviolet radiation absorbing agent and latex particles. CONSTITUTION: This ultraviolet radiation absorbing composition contains at least one ultraviolet radiation absorbing agent (e.g. oxybenzone or 2-ethoxyethyl p-methoxycinnamate) and latex particles having about 5-500 nm particle diameter and about 5-20% porosity in an amount of about 0.1-50% based on the total weight of nonvolatiles. Thereby, the amount of the ultraviolet radiation absorbing agent present in the formulation can be reduced while improving the ultraviolet radiation absorptivity or maintaining the prescribed ultraviolet radiation absorptivity. The composition is useful for improving the ultraviolet radiation absorptivity in body care products, etc., including a cosmetic used for human skin or hair, an antisuntan agent, a hair care product, etc.  The composition is further useful for improving the ultraviolet radiation absorptivity and protection of coatings in, e.g. a clear varnish state in plants, plastics or wood.
Patients receive dabrafenib PO BID and trametinib PO QD for 25 days. Patients then receive ipilimumab IV over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
Method for the preparation of 2-tiometil-furanos 5-substituidos. Is to react the compound of general formula (I) in which x is a chlorine or bromo atomo or a group isothyoureidico with sulfidrates of alkaline or hydrolyzed metals. Like sulfidrates sodium potassium is used. The hydrolysis of the isotioureidic group is effected with sodium or potassium hydroxide. It works in protic solvents like lower alcohols and/or water. The operating temperature is composed between the reflux and the environment. Compounds are obtained from general formula (II). (Machine-translation by Google Translate, not legally binding)
The invention belongs to the field of biological medicine, and particularly relates to a multiple small nucleic acid delivery system and a multiple target vaccine. The invention aims to solve the technical problem that the single target point in the biological tumor treatment has an unsatisfactory treatment effect. The technical scheme for solving the technical problem is to provide a multiple small nucleic acid transmission system for loading a plurality of small nucleic acids by hydrophobically modified polypeptides. The sequence of the polypeptide is VQWRIRVAVIRK, and the hydrophobic modification is to couple a hydrophobic fragment at the nitrogen end of the polypeptide. Meanwhile, the present invention provides a multiplex small nucleic acid system comprising siRNA molecules of STAT3, CCR2, TGF-beta and CpG ODNs molecules. The polypeptide and the small nucleic acid can be quickly self-assembled into nano micelles after being mixed to prepare a nano system for loading multiple small nucleic acids; when used as an in-situ vaccine carrier, the vaccine can treat different tumors aiming at different targets in tumor microenvironment; and the preparation method is low in toxicity, safe, short in preparation period and good in clinical application prospect.
A dragee coating contains from 0.7 to 14.3% of a vinyl polymer in addition to a sugar and any other desired additives.  The vinyl polymer may be polyvinyl pyrrolidone, polyvinyl acetate, a copolymer of vinyl pyrrolidone-vinyl acetate, polyvinyl alcohol and/or a copolymer of vinyl alcoholvinyl acetate.  The sugar may be sucrose, glucose, sorbitol or mannitol.  Cellulose derivatives e.g. methyl cellulose, starch, pigments, polishing agents, binders, plasticisers, or preservatives may be present in the coating.  The dragee cone, which may contain a steroid or pyridoxine hydrochloride, is coated with a coating suspension containing 0.5 to 10.0% of vinyl polymer by conventional techniques.  The suspension can be used on cones which have been precoated with a layer of varnish resistant to gastric juices.